Literature DB >> 10077725

Molecular genetic study of autosomal dominant retinitis pigmentosa in Lithuanian patients.

V Kucinskas1, A M Payne, D Ambrasiene, V Jurgelevicius, D Steponaviciūte, J V Arciuliene, E Daktaraviciene, S Bhattacharya.   

Abstract

Lithuanian patients with visual problems were clinically examined for retinitis pigmentosa (RP). A total of 33 unrelated families with autosomal dominant RP (adRP) were identified. Screening for mutations in the rhodopsin (RHO) and peripherin/RDS (RDS) genes was performed using DNA heteroduplex analysis. Direct DNA sequencing in the cases of heteroduplex formation showed the presence of the following mutations and polymorphisms in 14 adRP patients: RHO gene - Lys248Arg (1 case), and Pro347Leu (2 cases); RDS gene - Glu304Gln (12 cases), Lys310Arg (5 cases), and Gly338Asp (12 cases). The presence of these mutations (except Lys248Arg in the RHO gene) was confirmed by relevant restriction enzyme digestion. The frequency of the RDS gene mutations Glu304Gln and Gly338Asp was estimated to be 36.4%, while mutation Lys310Arg was less frequent (15.2%). These 3 RDS gene mutations appear to be polypeptide polymorphisms not related to adRP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077725     DOI: 10.1159/000022847

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  3 in total

Review 1.  The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.

Authors:  G B Arden
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 2.  Finding and interpreting genetic variations that are important to ophthalmologists.

Authors:  Edwin M Stone
Journal:  Trans Am Ophthalmol Soc       Date:  2003

3.  Mutation analysis of codons 345 and 347 of rhodopsin gene in Indian retinitis pigmentosa patients.

Authors:  M Dikshit; R Agarwal
Journal:  J Genet       Date:  2001-08       Impact factor: 1.508

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.